Patents Assigned to Pfizer Products Inc.
-
Patent number: 8999981Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: GrantFiled: January 6, 2012Date of Patent: April 7, 2015Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
-
Patent number: 8183230Abstract: The present invention is directed to pharmaceutical compositions containing a therapeutically effective amount of an Active Pharmaceutical Ingredient (“API”), a pharmaceutically acceptable cyclodextrin and a pharmaceutically acceptable preservative. The invention is also directed to pharmaceutical compositions of the compounds of Formula (I) wherein R2 is selected from the group consisting of methyl, ethyl, isopropyl, sec-butyl and tert-butyl and a pharmaceutically acceptable cyclodextrin and preservative. Formula (I): In particular, the invention is directed to pharmaceutical compositions of the compound of Formula 1a, and a pharmaceutically acceptable cyclodextrin and a preservative.Type: GrantFiled: January 17, 2005Date of Patent: May 22, 2012Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Roger C. Adami, Frederick David, Julia Ann Wood
-
Patent number: 8114871Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.Type: GrantFiled: April 10, 2008Date of Patent: February 14, 2012Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
-
Patent number: 8008078Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.Type: GrantFiled: April 23, 2008Date of Patent: August 30, 2011Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Kim J. Stutzman-Engwall, Anke Krebber, Claes Gustafsson, Jeremy S. Minshull, Sun Ai Raillard, Seran Kim, Yan Chen
-
Patent number: 7968584Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: GrantFiled: March 19, 2009Date of Patent: June 28, 2011Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7858340Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.Type: GrantFiled: June 11, 2003Date of Patent: December 28, 2010Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Kim J. Stutzman-Engwall, Yan Chen, Claes Gustafsson, Anke Krebber, Jeremy Minshull, Sun Ai Raillard
-
Patent number: 7820648Abstract: The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, salt thereof, wherein R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.Type: GrantFiled: December 20, 2006Date of Patent: October 26, 2010Assignees: Pfizer Inc, Pfizer Products IncInventors: Samit Kumar Bhattacharya, Michael Joseph Luzzio, Donn Gregory Wishka, Gonghua Pan, Arthur Douglas Brosius, Joel Thomas Arcari, James Alfred Southers, Jr., Kendra Louise Nelson, Jun Xiao
-
Patent number: 7803832Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.Type: GrantFiled: December 1, 2009Date of Patent: September 28, 2010Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
-
Patent number: 7687507Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: February 23, 2005Date of Patent: March 30, 2010Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown
-
Patent number: 7687533Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.Type: GrantFiled: March 7, 2005Date of Patent: March 30, 2010Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
-
Publication number: 20100056571Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.Type: ApplicationFiled: November 12, 2009Publication date: March 4, 2010Applicants: Pfizer Inc., Pfizer Products Inc.Inventors: Michael J. Munchhof, Laura C. Blumberg
-
Publication number: 20100029710Abstract: Compounds of following formula (I) are provided that have both angiotensin II receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the compounds including type 2 diabetes, insulin resistance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, congestive heart failure, and hypertension.Type: ApplicationFiled: December 3, 2007Publication date: February 4, 2010Applicant: Pfizer Products Inc.Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Chitase Lee, Hud Lawrence Risley, Robert Philip Schaum
-
Patent number: 7638537Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.Type: GrantFiled: November 8, 2006Date of Patent: December 29, 2009Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Michael J. Munchhof, Laura C. Blumberg
-
Patent number: 7635702Abstract: Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.Type: GrantFiled: November 10, 2006Date of Patent: December 22, 2009Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Michael J. Munchhof, Laura C. Blumberg
-
Publication number: 20090215857Abstract: The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 29, 2006Publication date: August 27, 2009Applicant: Pfizer Products Inc.Inventors: Thomas Bruno Lanni, Scott Edward Lazerwith, Susan Mary Kult Sheehan, Anthony Jerome Thomas
-
Publication number: 20090186924Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: ApplicationFiled: March 19, 2009Publication date: July 23, 2009Applicants: Pfizer Inc., Pfizer Products Inc..Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7538134Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: GrantFiled: June 14, 2006Date of Patent: May 26, 2009Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7417041Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.Type: GrantFiled: February 20, 2004Date of Patent: August 26, 2008Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
-
Patent number: 7378101Abstract: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided.Type: GrantFiled: May 21, 2004Date of Patent: May 27, 2008Assignees: Pfizer, Inc., Pfizer Products, Inc.Inventors: John Morgan Hardham, Kendall Wayne King, Rajendra Krishnan, Kimberly Jean Dreier, David Ross McGavin, John David Haworth
-
Patent number: 7378408Abstract: Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats.Type: GrantFiled: November 12, 2002Date of Patent: May 27, 2008Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Roger N. Kimball, Renuka D. Reddy, Evgenyi Y. Shalaev